Tafluprost Patent Expiration
Tafluprost is used for reducing elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. It was first introduced by Thea Pharma Inc
Tafluprost Patents
Given below is the list of patents protecting Tafluprost, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zioptan | US10864159 | Method and composition for treating ocular hypertension and glaucoma | May 28, 2029 | Thea Pharma |
| Zioptan | US5886035 | Difluoroprostaglandin derivatives and their use |
Dec 18, 2017
(Expired) | Thea Pharma |
| Zioptan | US9999593 | Method and composition for treating ocular hypertension and glaucoma | May 28, 2029 | Thea Pharma |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tafluprost's patents.
Latest Legal Activities on Tafluprost's Patents
Given below is the list recent legal activities going on the following patents of Tafluprost.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 29 May, 2024 | US10864159 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 Dec, 2021 | US9999593 |
| Patent Issue Date Used in PTA Calculation | 15 Dec, 2020 | US10864159 |
| Recordation of Patent Grant Mailed | 15 Dec, 2020 | US10864159 |
| Email Notification | 25 Nov, 2020 | US10864159 |
| Issue Notification Mailed | 24 Nov, 2020 | US10864159 |
| Application Is Considered Ready for Issue | 12 Nov, 2020 | US10864159 |
| Dispatch to FDC | 12 Nov, 2020 | US10864159 |
| Issue Fee Payment Received | 11 Nov, 2020 | US10864159 |
| Issue Fee Payment Verified | 11 Nov, 2020 | US10864159 |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Tafluprost Generics
Several generic applications have been filed for Tafluprost. The first generic version for Tafluprost was by Micro Labs Ltd and was approved on Aug 19, 2019. And the latest generic version is by Ingenus Pharmaceuticals Llc and was approved on Apr 5, 2024.
Given below is the list of companies who have filed for Tafluprost generic.
1. SANDOZ
Sandoz Inc has filed for 1 generic for Tafluprost. Given below are the details of the strengths of this generic introduced by Sandoz.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.0015% | solution/drops | Prescription | OPHTHALMIC | AT | Jan 28, 2022 |
2. INGENUS PHARMS LLC
Ingenus Pharmaceuticals Llc has filed for 1 generic for Tafluprost. Given below are the details of the strengths of this generic introduced by Ingenus Pharms Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.0015% | solution/drops | Discontinued | OPHTHALMIC | N/A | Apr 5, 2024 |
3. MICRO LABS
Micro Labs Ltd has filed for 1 generic for Tafluprost. Given below are the details of the strengths of this generic introduced by Micro Labs.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.0015% | solution/drops | Prescription | OPHTHALMIC | AT | Aug 19, 2019 |